Do analysts prefer TXMD or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor NRSN or CDIO?

In the previous week, NeuroSense Therapeutics and NeuroSense Therapeutics both had 2 articles in the media. NeuroSense Therapeutics' average media sentiment score of 1.13 beat Cardio Diagnostics' score of 0.94 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NCEL or CDIO?

NLS Pharmaceutics presently has a consensus price target of $23.00, suggesting a potential upside of 525.00%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities analysts clearly believe NLS Pharmaceutics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, NCEL or CDIO?

Cardio Diagnostics has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Cardio Diagnostics $16.57K 305.92 -$6.50M -$3.38 N/A

Do analysts prefer CDIO or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend VYNE or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor VYNE or CDIO?

In the previous week, VYNE Therapeutics had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 4 mentions for VYNE Therapeutics and 2 mentions for Cardio Diagnostics. VYNE Therapeutics' average media sentiment score of 1.15 beat Cardio Diagnostics' score of 0.94 indicating that VYNE Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VYNE Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cardio Diagnostics (CDIO) Competitors

$1.71 -0.08 (-4.47%)

As of 01:44 PM Eastern

Compare

CDIO vs. TXMD, NRSN, NCEL, ZIVO, and VYNE

Should you buy Cardio Diagnostics stock or one of its competitors? MarketBeat compares Cardio Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardio Diagnostics include TherapeuticsMD (TXMD), NeuroSense Therapeutics (NRSN), NLS Pharmaceutics (NCEL), ZIVO Bioscience (ZIVO), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry.

How does Cardio Diagnostics compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Cardio Diagnostics had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for Cardio Diagnostics and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.89 beat Cardio Diagnostics' score of 0.94 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Cardio Diagnostics	Positive

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

TherapeuticsMD has higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.85	-$570K	$0.06	34.17
Cardio Diagnostics	$16.57K	305.92	-$6.50M	-$3.38	N/A

TherapeuticsMD has a net margin of 5.34% compared to Cardio Diagnostics' net margin of -36,950.00%. TherapeuticsMD's return on equity of 0.32% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

TherapeuticsMD has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats Cardio Diagnostics on 9 of the 13 factors compared between the two stocks.

How does Cardio Diagnostics compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

NeuroSense Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. NeuroSense Therapeutics' return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Cardio Diagnostics has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Cardio Diagnostics	$16.57K	305.92	-$6.50M	-$3.38	N/A

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NeuroSense Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 1,098.87%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe NeuroSense Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, NeuroSense Therapeutics and NeuroSense Therapeutics both had 2 articles in the media. NeuroSense Therapeutics' average media sentiment score of 1.13 beat Cardio Diagnostics' score of 0.94 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroSense Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

Summary

NeuroSense Therapeutics beats Cardio Diagnostics on 10 of the 15 factors compared between the two stocks.

How does Cardio Diagnostics compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

NLS Pharmaceutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

NLS Pharmaceutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. NLS Pharmaceutics' return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Cardio Diagnostics has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Cardio Diagnostics	$16.57K	305.92	-$6.50M	-$3.38	N/A

NLS Pharmaceutics presently has a consensus price target of $23.00, suggesting a potential upside of 525.00%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities analysts clearly believe NLS Pharmaceutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.1% of Cardio Diagnostics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 2 articles in the media. Cardio Diagnostics' average media sentiment score of 0.94 beat NLS Pharmaceutics' score of 0.72 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
Cardio Diagnostics	Positive

Summary

NLS Pharmaceutics beats Cardio Diagnostics on 7 of the 12 factors compared between the two stocks.

How does Cardio Diagnostics compare to ZIVO Bioscience?

Cardio Diagnostics (NASDAQ:CDIO) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

ZIVO Bioscience has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. ZIVO Bioscience's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Cardio Diagnostics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

In the previous week, Cardio Diagnostics had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Cardio Diagnostics and 0 mentions for ZIVO Bioscience. Cardio Diagnostics' average media sentiment score of 0.94 beat ZIVO Bioscience's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardio Diagnostics	Positive
ZIVO Bioscience	Neutral

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 13.3% of Cardio Diagnostics shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cardio Diagnostics has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$16.57K	305.92	-$6.50M	-$3.38	N/A
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A

Summary

Cardio Diagnostics beats ZIVO Bioscience on 8 of the 14 factors compared between the two stocks.

How does Cardio Diagnostics compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Cardio Diagnostics has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$454K	57.38	-$26.48M	-$0.38	N/A
Cardio Diagnostics	$16.57K	305.92	-$6.50M	-$3.38	N/A

VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market.

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, VYNE Therapeutics had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 4 mentions for VYNE Therapeutics and 2 mentions for Cardio Diagnostics. VYNE Therapeutics' average media sentiment score of 1.15 beat Cardio Diagnostics' score of 0.94 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VYNE Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

VYNE Therapeutics has a net margin of -4,726.21% compared to Cardio Diagnostics' net margin of -36,950.00%. VYNE Therapeutics' return on equity of -70.42% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Summary

VYNE Therapeutics beats Cardio Diagnostics on 9 of the 14 factors compared between the two stocks.

Get Cardio Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDIO vs. The Competition

Export

Metric	Cardio Diagnostics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.07M	$3.67B	$6.85B	$12.56B
Dividend Yield	N/A	2.22%	2.68%	9.45%
P/E Ratio	-0.51	21.10	27.17	24.29
Price / Sales	305.92	176.62	510.33	88.09
Price / Cash	N/A	143.89	48.63	60.03
Price / Book	0.45	8.41	10.81	6.24
Net Income	-$6.50M	$23.83M	$3.59B	$331.73M
7 Day Performance	-7.46%	-5.08%	-2.34%	-1.70%
1 Month Performance	-12.65%	5.40%	3.01%	-0.76%
1 Year Performance	-62.78%	45.66%	25.50%	18.46%

Cardio Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDIO Cardio Diagnostics	0.4097 of 5 stars	$1.71 -4.4%	N/A	-59.9%	$5.07M	$16.57K	N/A	1	Gap Down
TXMD TherapeuticsMD	1.3333 of 5 stars	$1.96 -0.5%	N/A	+70.9%	$22.68M	$3.02M	32.67	420
NRSN NeuroSense Therapeutics	3.5058 of 5 stars	$0.68 -3.4%	$8.50 +1,142.7%	-63.7%	$22.27M	N/A	N/A	10	Gap Down
NCEL NLS Pharmaceutics	3.5947 of 5 stars	$4.09 +2.0%	N/A	-82.1%	$21.88M	N/A	N/A	6	Analyst Forecast Gap Down
ZIVO ZIVO Bioscience	N/A	$5.25 flat	N/A	-67.3%	$21.80M	$15.85K	N/A	10	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDIO) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardio Diagnostics (CDIO) Competitors

CDIO vs. TXMD, NRSN, NCEL, ZIVO, and VYNE

How does Cardio Diagnostics compare to TherapeuticsMD?

Summary

How does Cardio Diagnostics compare to NeuroSense Therapeutics?

Summary

How does Cardio Diagnostics compare to NLS Pharmaceutics?

Summary

How does Cardio Diagnostics compare to ZIVO Bioscience?

Summary

How does Cardio Diagnostics compare to VYNE Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardio Diagnostics (CDIO) Competitors

CDIO vs. TXMD, NRSN, NCEL, ZIVO, and VYNE

How does Cardio Diagnostics compare to TherapeuticsMD?

Does the media favor TXMD or CDIO?

Do institutionals and insiders have more ownership in TXMD or CDIO?

Which has stronger valuation and earnings, TXMD or CDIO?

Is TXMD or CDIO more profitable?

Which has more volatility and risk, TXMD or CDIO?

Do analysts prefer TXMD or CDIO?

Summary

How does Cardio Diagnostics compare to NeuroSense Therapeutics?

Is NRSN or CDIO more profitable?

Which has preferable earnings & valuation, NRSN or CDIO?

Do insiders and institutionals believe in NRSN or CDIO?

Do analysts recommend NRSN or CDIO?

Does the media favor NRSN or CDIO?

Which has more volatility & risk, NRSN or CDIO?

Summary

How does Cardio Diagnostics compare to NLS Pharmaceutics?

Which has more risk & volatility, NCEL or CDIO?

Is NCEL or CDIO more profitable?

Which has higher earnings & valuation, NCEL or CDIO?

Do analysts rate NCEL or CDIO?

Do insiders & institutionals hold more shares of NCEL or CDIO?

Does the media favor NCEL or CDIO?

Summary

How does Cardio Diagnostics compare to ZIVO Bioscience?

Is CDIO or ZIVO more profitable?

Which has more volatility and risk, CDIO or ZIVO?

Does the media refer more to CDIO or ZIVO?

Do institutionals and insiders hold more shares of CDIO or ZIVO?

Do analysts prefer CDIO or ZIVO?

Which has stronger valuation and earnings, CDIO or ZIVO?

Summary

How does Cardio Diagnostics compare to VYNE Therapeutics?

Which has stronger valuation & earnings, VYNE or CDIO?

Which has more risk and volatility, VYNE or CDIO?

Do institutionals and insiders have more ownership in VYNE or CDIO?

Do analysts recommend VYNE or CDIO?

Does the media favor VYNE or CDIO?

Is VYNE or CDIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools